Reminders, Cost Sharing, and Healthcare Use

August 23, 2022 updated by: Lauri Sääksvuori, Finnish Institute for Health and Welfare

The investigators conduct a large-scale randomized controlled trial in Finland by sending three types of information letters to households to examine whether the reminder letters affect healthcare use. All letters remind of the importance of seeking care to treat potential health problems.

This study has two primary objectives are: to evaluate the effects of an information nudge reminding on the importance of diagnosing and treating health problems and to evaluate the effects of additionally providing information on the fact that primary care nurse visits have become exempt from copayments. Main outcomes include the number of primary care nurse visits and general practitioner (GP) visits in a six-month follow-up.

Study Overview

Detailed Description

This study has two main objectives: (i) to evaluate the effect of an information nudge reminding on the importance of diagnosing and treating health problems and (ii) to evaluate the effect of providing information on the fact that primary care nurse visits have become exempt from co-payments.

Study Type

Interventional

Enrollment (Actual)

47398

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Helsinki, Finland, 00271
        • Finnish Institute for Health and Welfare

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Residency in one of the 25 target municipalities as of September 15, 2021.
  • Born in 1966 or earlier (aged 55 or more at the end of 2021).
  • Living in a household with a maximum of three individuals aged 55 or above.

Exclusion Criteria:

  • Individuals living in households (postal address) with more than three individuals aged 55 and above.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Basic letter
This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed.
Reminders
Active Comparator: Co-pay
This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed AND informs recipients about a new law that abolished all co-payments for all primary care nurse visits in Finland.
Reminders
Active Comparator: GP-Co-pay
This reminder states that if healthcare is not consumed at the right time, health may deteriorate and diagnoses and treatment may be delayed AND informs recipients about a new law that abolished all co-payments for all primary care nurse visits in Finland, AND informs recipients that the new law did not abolish co-payments related to general practitioner visits.
Reminders
No Intervention: Control treatment
There is no intervention in the control treatment. The entire population aged 55 and above in the treatment regions will serve as a control group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of nurse visits (as recorded in the Finnish National Register of Primary Health Care Visits)
Time Frame: Six months starting from the date the letters are sent
Six months starting from the date the letters are sent
Number of doctor visits (as recorded in the Finnish National Register of Primary Health Care Visits)
Time Frame: Six months starting from the date the letters are sent
Six months starting from the date the letters are sent

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of referrals to specialized care (as recorded in the Finnish National Register of Primary Health Care Visits)
Time Frame: Six months starting from the date the letters are sent
Six months starting from the date the letters are sent
Number of drug prescriptions for newly initiated therapies (as recorded in the Finnish national register for prescribed medicines)
Time Frame: Six months starting from the date the letters are sent
Six months starting from the date the letters are sent

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lauri Sääksvuori, PhD, Finnish Institute for Health and Welfare and University of Turku

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2021

Primary Completion (Actual)

April 1, 2022

Study Completion (Actual)

April 1, 2022

Study Registration Dates

First Submitted

October 5, 2021

First Submitted That Met QC Criteria

November 2, 2021

First Posted (Actual)

November 11, 2021

Study Record Updates

Last Update Posted (Actual)

August 26, 2022

Last Update Submitted That Met QC Criteria

August 23, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • THL/3181/6.02.01/2021

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This paper uses administrative health records maintained by the Finnish Institute for Health and Welfare. Access to health records is regulated in Finland under the Act on the Secondary Use of Health and Social Data (552/2019). De-identified individual participant data will be shared subject to approval by the competent data protection authority. All statistical code used to organize and analyze the data will be shared.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Health Behavior

Clinical Trials on Reminder (information letter)

3
Subscribe